Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Pradaxa | Research | Study